Characteristic | Training cohort (n = 137) | P | Independent validation cohort (n = 54) | P | ||
---|---|---|---|---|---|---|
pGR (n = 57) | Non-pGR (n = 80) | pGR (n = 25) | Non-pGR (n = 29) | |||
Age, years | ||||||
 Median (range) | 16 (4.6–43) | 14 (4–46) | 0.3939 | 15 (8–39) | 18 (7–44) | 0.6123 |
  ≤ 15 y | 27 | 45 |  | 13 | 12 |  |
  > 15 y | 30 | 35 |  | 12 | 17 |  |
Gender | Â | Â | 1 | Â | Â | 0.5852 |
 Male | 34 | 47 |  | 14 | 13 |  |
 Female | 23 | 33 |  | 11 | 16 |  |
Location of primary tumor | Â | Â | 0.3447 | Â | Â | 0.8041 |
 Humerus | 11 | 8 |  | 3 | 3 |  |
 Femur | 27 | 45 |  | 14 | 17 |  |
 Tibia and fibula | 17 | 20 |  | 8 | 8 |  |
 Radius and ulna | 1 | 2 |  | 0 | 0 |  |
 Others | 1 | 5 |  | 0 | 1 |  |
Stage at diagnosis | Â | Â | 1 | Â | Â | 0.3062 |
 Localized | 47 | 66 |  | 20 | 27 |  |
 Metastatic | 10 | 14 |  | 5 | 2 |  |
Pathologic subtype | Â | Â | 0.3055 | Â | Â | 0.332 |
 Osteoblastic | 46 | 55 |  | 20 | 19 |  |
 Chondroblastic | 3 | 13 |  | 1 | 5 |  |
 Fibroblastic | 4 | 4 |  | 4 | 4 |  |
 Telangiectatic | 3 | 5 |  | 0 | 1 |  |
 Others | 1 | 3 |  | 0 | 0 |  |
Type of surgery | Â | Â | 0.02487* | Â | Â | 1 |
 Limb salvage | 55 | 66 |  | 24 | 27 |  |
 Amputation | 2 | 14 |  | 1 | 2 |  |
New pulmonary metastasis | Â | Â | 1 | Â | Â | 0.9402 |
 Yes | 2 | 4 |  | 1 | 0 |  |
 No | 55 | 76 |  | 24 | 29 |  |
Chemotherapy regimens | Â | Â | 0.7224 | Â | Â | 0.4406 |
 1MTX, DDP and ADM | 42 | 58 |  | 17 | 22 |  |
 2MTX, IFO,DDP and ADM | 12 | 15 |  | 8 | 6 |  |
 3MTX,IFO, DDP and ADM | 3 | 7 |  | 0 | 1 |  |
 Radiomics score | 4.4E-4(−1.1–0.72) | −0.55(−2.9–0.32) | 2.1E-14 | 0.030(−0.58–0.71) | −0.31(−2.1–0.34) | 2.4E-5 |